



iCHOR iDVT Limited Market Release Data; Commercial Experience Report

Real-World Evidence Supporting Adoption, Repeat Utilization and
Commercial Expansion

Executive Summary

The iCHOR iDVT commercial evaluation program provides real-world evidence of physician adoption, procedural performance, and repeat utilization across a growing network of users.

Since its commercial introduction, the iDVT platform has been utilized in 77 documented procedures by 20 physicians treating a broad range of venous thrombotic disease. The data demonstrate strong physician acceptance, high procedural success, repeat utilization among active users, and consistently positive workflow feedback.

The most significant commercial indicator is the emergence of repeat utilization. Physicians who progressed beyond initial evaluation accounted for the vast majority of procedures performed, suggesting successful integration of the device into routine clinical practice.

Commercial Validation Dashboard

Metric	Result
Documented Procedures	77
Participating Physicians	20
Technical Success Rate	95%
Procedural Success Rate	93.5%
Repeat User Procedures	88.3%
Future Use Responses	100% Positive
Average iDVT Treatment Time	29.4 Minutes
Average Treatment Zone	231 mm

Key Highlights

- 77 commercial procedures completed across 20 physicians.
- 93.5% reported procedural success.
- 88.3% of all procedures were performed by repeat users.
- <5mL of blood loss observed across most procedures.
- Physicians providing future-use feedback indicated willingness to continue using the device.
- Five physicians progressed to high-frequency utilization with more than five documented procedures.

Physician Adoption and Commercial Traction

Repeat Utilization is Emerging

The strongest indicator of commercial adoption is not first-time use but repeat utilization. Of the 20 physicians represented in the dataset, 11 progressed beyond initial evaluation and continued to use the device in subsequent cases.

These repeat users accounted for 68 of the 77 documented procedures, representing 88.3% of all cases performed.

Adoption Profile

User Category	Physicians
>5 Procedure	5
2–5 Procedures	6
Single Evaluation Procedure	9

Top Physician Utilization

Physician	Procedures
Bernardino Rocha	18
Edward Arous	15
Chong Li	8
William Harris	7
Micah Girotti	6

The five most active physicians performed 54 procedures, representing 70.1% of all documented commercial experience.

This concentration is consistent with early-stage commercialization, where initial adoption is typically driven by physician champions and high-volume thrombectomy users.



Procedural Performance

Consistent Performance Across Diverse Thrombus Burdens

The commercial evaluation dataset includes treatment across multiple venous territories, vessel diameters, thrombus burdens, and physician experience levels.

Procedure Metrics

Metric	Result
Mean iDVT Treatment Time*	29.4 min
Median iDVT Treatment Time *	26.0 min
Average Passes	5.0
Average Vessel Diameter	13.2 mm
Average Clot Removed	231 mm
Median Clot Removed	200 mm
Average Residual Thrombus**	20.6%

The dataset demonstrates consistent device utilization across a broad range of procedural scenarios while maintaining favorable workflow characteristics.

*Treatment Time includes: device opened, clot sweeps, flow restored, treatment of underlying lesion, closure.

**Residual Thrombus metric driven by ~9 procedures that were complex, often beyond organized thrombus into chronic occlusions, jailed stents or other complex issues that any device could struggle with. Data is helpful in messaging areas iCHOR might find challenging.

Device Performance Ratings

Physicians consistently rated device performance highly across multiple workflow categories.

Category	Average Rating (1–5)
Packaging	4.48
Nitinol Funnel	4.78
Balloon Tracking	4.81
Ease of Delivery	4.69

Ratings clustered near the top of the scale, reflecting strong physician satisfaction with device handling and procedural workflow.



Physician Experience

Voice of the Customer

Qualitative feedback from physicians provides additional insight into the perceived value of the iDVT platform.

Physician Comments

- "I might use 50 of these before the year is over."
- "Device performed really well."
- "Probably the most clot burden we have seen in a patient - represents the worst-case scenario and we had a great patient outcome."

Common Themes

- Effective thrombus extraction
- Simple procedural workflow
- Strong catheter tracking
- Ease of device delivery
- Familiar operating technique
- Minimal learning curve
- Integration into existing thrombectomy practice

Physician feedback consistently highlighted workflow simplicity and the ability to effectively manage substantial thrombus burden without introducing significant procedural complexity.



Commercial Outlook

Evidence Supporting Commercial Expansion

The commercial evaluation experience demonstrates several important indicators of market acceptance.

Adoption

The transition from evaluation procedures to repeat utilization suggests growing physician confidence and integration into routine practice.

Clinical Utility

The device has been used successfully across a broad range of thrombus burdens, vessel sizes, and clinical scenarios.

Workflow Simplicity

Average procedure times, high usability ratings, and positive physician feedback support the platform's ease of use.

Economic Alignment

The absence of aspiration pumps, thrombolytic infusion systems, or capital equipment requirements creates a workflow that aligns with hospital, office-based laboratory (OBL), and ambulatory surgery center (ASC) environments.

Conclusion

The iCHOR iDVT commercial evaluation program has generated a growing body of real-world experience across 77 documented procedures and 20 physicians.

The data demonstrates strong physician acceptance, high procedural success, repeat utilization among active users, favorable workflow characteristics, and consistently positive physician feedback.

Collectively, these findings provide meaningful evidence supporting continued commercial expansion and broader market adoption of the iDVT platform.